Pharmacy Times® interviewed Jason Kay, PharmD, MS, the director of pharmacy programs at of Blue Cross Blue Shield Association, on how the recent drop in immunizations among children may result in the rise of certain highly contagious diseases.
Pharmacy Times® interviewed Michael Flannery, PharmD, the assistant director of pharmacy operations at the University of Rochester Medical Center, on the concerns he has regarding the COVID-19 vaccination process ahead.
Pharmacy Times® interviewed Emily Cook, JD, a partner with McDermott Will & Emery, on the final 340B dispute resolution rule, which was recently sent by the HHS to the OMB for review.
Pharmacy Times® interviewed Sue Peschin of the COVID-19 Vaccine Education and Equity Project on the role of pharmacies in vaccinating the public with the COVID-19 vaccines.
Pharmacy Times® interviewed Sue Peschin, president and CEO of Alliance for Aging Research, on the work that the COVID-19 Vaccine Education and Equity Project is doing to engage diverse constituencies on the importance of the clinical trials process, regulatory review, and equitable access to COVID-19 vaccines.
Pharmacy Times® interviewed Sue Peschin, president and CEO of Alliance for Aging Research, on the work that the COVID-19 Vaccine Education and Equity Project is doing to support education about and equitable access to COVID-19 vaccines.
Pharmacists, physicians, and nurses have been among the first to receive COVID-19 vaccinations at health care facilities across the country.
Pharmacy Times® interviewed John Beckner, the senior director of strategic initiatives at the National Community Pharmacists Association, on how pharmacists can help people come back for the second dose of the COVID-19 vaccine.
Pharmacy Times® interviewed John Beckner, the senior director of strategic initiatives at the National Community Pharmacists Association, on some of the challenges community pharmacies may need to manage when receiving and administering COVID-19 vaccines.
Pharmacy Times® interviewed John Beckner, the senior director of strategic initiatives at the National Community Pharmacists Association, on the work needed to prepare for the arrival and administration of COVID-19 vaccines.
Rami Komrokji, MD, discusses what the MOST study's results mean for investigating second-line treatment options in myelofibrosis.
Rami Komrokji, MD, discusses whether the majority of patients in the MOST study were being treated at the time of enrollment, and why real-world data is so essential.
Pharmacy Times® interviewed Signe Pringle, the assistant secretary for the Maryland Department of Commerce, on a signed partnership between Quebec and Maryland to foster collaboration around health science research during COVID-19 and beyond.
Rami Komrokji, MD, discusses common prior treatments of low-risk and intermediate-1 risk patients in the MOST study.
In an interview with Pharmacy Times, Helen Thackray, MD, Thackray describes what she hopes to see for future trials involving sickle cell disease and rivipansel for acute vaso-occlusive crisis.
In an interview with Pharmacy Times, Helen Thackray, MD, Thackray emphasizes the importance of administering rivipansel early in vaso-occlusive crisis and how it is meaningful for both adults and children with sickle cell disease.
Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about factors in treatment decisions for patients with myelofibrosis.
In an interview with Pharmacy Times, Helen Thackray, MD, reveals what finding she believes was the most interesting after analyzing the results of the RESET clinical trial, which covers the early initiation with rivipansel for acute vaso-occulusive crisis in sickle cell disease.
Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses closing thoughts on the results of the study and its implications for future treatment options for patients with relapsed/refractory multiple myeloma.
Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses what the implications of the high rate of dose holds that occurred in the study were, and whether there any plans to address this concern in the future.
Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what his team’s plans are for the evaluation of ponatinib during the remaining portion of the OPTIC trial, which is currently ongoing.
Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses whether the treatment emergent adverse events (AEs) were consistent with the known safety profiles for belantamab mafodotin and pomalidomide.
Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses common adverse events (AEs) observed in patients with relapsed/refractory multiple myeloma following treatment with belantamab mafodotin in combination with pomalidomide and dexamethasone.
Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what the interim analysis of the OPTIC trial demonstrated in terms of the safety and arterial occlusive events profiles with response-based ponatinib dosing regimens.
Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses the common prior therapies for patients with relapsed/refractory multiple myeloma who were enrolled in the ALGONQUIN trial.
Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what the PACE trial was able to demonstrate in regard to patient response to ponatinib for patients with resistant and intolerant chronic-phase CML with substantial prior second-generation treatment.
Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses the dose limiting toxicities observed among patients with relapsed/refractory multiple myeloma following treatment with belantamab mafodotin in combination with pomalidomide and dexamethasone.
Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses what belantamab mafodotin and pomalidomide are, and how they work together to treat relapsed/refractory multiple myeloma.
Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses the reasons that the use of second-generation tyrosine kinase inhibitors in patients with chronic-phase CML who have failed one or more second-generation tyrosine kinase inhibitors needed further investigation.
Helen Thackray, MD, dives deeper into how the researchers tested rivipansel on the study participants and the implications compared to previous trials.
